dawdy_ferman_family_conference_room _2016
TRANSCRIPT
![Page 1: Dawdy_Ferman_Family_Conference_Room _2016](https://reader031.vdocuments.us/reader031/viewer/2022030308/58ee65471a28ab304c8b4637/html5/thumbnails/1.jpg)
PROTEOMICS
Rapid Measurement of Lung Cancer Biomarkers
Ambermarie Dawdy
August 01, 2016
Jin H. Park, Biochem J., 2012,448(Pt 3): 417-423
![Page 2: Dawdy_Ferman_Family_Conference_Room _2016](https://reader031.vdocuments.us/reader031/viewer/2022030308/58ee65471a28ab304c8b4637/html5/thumbnails/2.jpg)
Why Should we Study Lung Cancer?
Rebecca L. Siegel, CA CANCER J CLIN 2016,66, 11-18
Estimated New Cases
Prostate 21% Lung & Bronchus 14%Colon & Rectum 8%Urinary Bladder 7%Melanoma 6%Lymphoma 5%Kidney & Renal 5%Oral & Pharynx 4%Leukemia 4%Liver & Bile Duct 3%
Lung & Bronchus 27%Prostate 8%Colon & Rectum 8%Pancreas 7%Liver & Bile Duct 3%Leukemia 4%Esophagus 4%Urinary Bladder 4%Lymphoma 4%Brain & Nervous 3%
Breast Lung & Bronchus Colon & Rectum Uterine corpus Thyroid Lymphoma Melanoma Leukemia Pancreas Kidney & Renal
Lung & BronchusBreast Colon & Rectum Pancreas Ovary Uterine corpus Leukemia Liver & Bile Duct Lymphoma Brain & Nervous
Estimated Deaths
29%13%
8%7%6%4%3%3%3%3%
26%14%
8%7%5%4%4%3%3%2%
*17,369 Cases of estimated new cases in Florida and 11,960 estimated deaths from lung cancer
![Page 3: Dawdy_Ferman_Family_Conference_Room _2016](https://reader031.vdocuments.us/reader031/viewer/2022030308/58ee65471a28ab304c8b4637/html5/thumbnails/3.jpg)
What are Biomarkers?• Measurable substances in
organisms whose presence is indicative of a biological occurrence such as disease/infection
• Tissue microarray is used to remove sections of tumor tissue and clinical biopsies
• Reduces the time it takes to process tissue microarrays from 3 hours a sample to 12 minutes a sample
Mascaux C, Clin Cancer Res, 2011,17, 7801
![Page 4: Dawdy_Ferman_Family_Conference_Room _2016](https://reader031.vdocuments.us/reader031/viewer/2022030308/58ee65471a28ab304c8b4637/html5/thumbnails/4.jpg)
Methods
![Page 5: Dawdy_Ferman_Family_Conference_Room _2016](https://reader031.vdocuments.us/reader031/viewer/2022030308/58ee65471a28ab304c8b4637/html5/thumbnails/5.jpg)
Cellularity Biomarker: Lamin-A/C
Library A549 H1648 H1650 H1975 H322 HCC2279 HCC827
Lamin Protein Structure
SGAQASSTPLSPTR
Quigley A, Science ,2013,339:1604-1607
![Page 6: Dawdy_Ferman_Family_Conference_Room _2016](https://reader031.vdocuments.us/reader031/viewer/2022030308/58ee65471a28ab304c8b4637/html5/thumbnails/6.jpg)
Cellularity Biomarker: Epidermal Growth Factor Receptor
Library A549 H1648 H1650 H1975 H322 HCC2279 HCC827
.LTQLGTFEDHFLSLQR
EGFR STRUCTUREErlotinib Structure
![Page 7: Dawdy_Ferman_Family_Conference_Room _2016](https://reader031.vdocuments.us/reader031/viewer/2022030308/58ee65471a28ab304c8b4637/html5/thumbnails/7.jpg)
SUMMARY
● Lung Cancer has Poor Patient Outcomes
● Improved assessment of biomarkers can help the patient
● Goal: Develop and implement new methods for biomarker detection
![Page 8: Dawdy_Ferman_Family_Conference_Room _2016](https://reader031.vdocuments.us/reader031/viewer/2022030308/58ee65471a28ab304c8b4637/html5/thumbnails/8.jpg)
Acknowledgments
Funding: Frank E. Duckwall Foundation, Saunders Foundation, Moffitt Cancer Center
Koomen LabJohn Koomen, PhDMelissa MartinezOmar Chavez-Chiang, MD
Proteomics CoreBin Fang, PhDLancia Darville, PhDVictoria IzumiKiah Bowers
SPARKDoug Cress, PhDEvelyn Rivera-Miranda
Moffitt Cancer Center Moffitt Foundation